

# Trend of Opdivo


November 7, 2017

# Value

## Composition ratio of Opdivo (New patients and continuously treated patients)

Actual consumption value  
(calculated by wholesale price)

Million Yen




## No. of patients

# Composition ratio of Opdivo (New patients and continuously treated patients)

Estimated No. of patients

■ New patients

■ Continuously treated patients



# Average treatment period of Opdivo by each cancer

## Estimated treatment period

The following average treatment period of each cancer is estimated from the PFS Kaplan-Meier curves by treatment line during the clinical development .

|                    |                    |
|--------------------|--------------------|
| Melanoma           | : 5 months         |
| Lung cancer        | : 4.5 months       |
| Renal cancer       | : 9.5 months       |
| Hodgkin lymphoma   | : 18 months        |
| Head & neck cancer | : About 4.5 months |

## Average treatment period of Opdivo in lung cancer from DPC receipt data

**Subjects: Patients started treatment within 3 months immediately after approval for lung cancer**

**Average treatment period:**   2ndL 5 months  
                                          3rdL 3 months


**Note:** It is anticipated that the average treatment period will be further prolonged along the time, because patients currently under the treatment is included among them.



---

# Gastric Cancer


# Patient Flow(2017)



Source: CancerMPact. 2017

# No. of GC patients with Opdivo prescription

Person (s)



# Positioning status of Opdivo by Doctors

Nationwide

## Positioning of Opdivo

